glp-1 bmi 25 A Balancing Act: Receptor Agonists for Non-Diabetic Obesity – Clinical Correlations VisualAbstract: Once-weekly Semaglutide Reduces Body

What started as a treatment for type 2 diabetes has rapidly evolved into a platform therapy influencing obesity, cardiovascular disease, fatty liver disease, neurodegeneration, inflammation, and potentially oncology

Beyond their metabolic benefits, GLP-1 RAs exhibit neuroprotective and psychotropic effects, potentially benefiting mental health conditions like depression and anxiety

Novo Nordisk Signs Deal with Hims & Hers Mike Hollan Key Takeaways Novo Nordisks telehealth distribution strategy now includes Hims & Hers, offering multiple Ozempic injection doses and a broad Wegovy dose range across injectable and tablet formulations for DTC channels

Why this matters: Eliminates the need for injection Non-peptide structure A CMC & Innovation Perspective: Transitioning GLP-1 therapies from peptide injectables to oral small molecules reflects a paradigm shift in: Drug design & stability Supply chain efficiency Cost of goods & scalability Role of CMC Competitive Intelligence: Benchmarking against injectable GLP-1s

In other cases, temporarily pausing or reducing the dose may help your eyes stabilize